<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medlit</journal-id><journal-title-group><journal-title xml:lang="ru">Гигиена и санитария</journal-title><trans-title-group xml:lang="en"><trans-title>Hygiene and Sanitation</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0016-9900</issn><issn pub-type="epub">2412-0650</issn><publisher><publisher-name>Federal Scientific Center of Hygiene named after F.F. Erisman</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47470/0016-9900-2024-103-11-1417-1422</article-id><article-id custom-type="edn" pub-id-type="custom">omdcez</article-id><article-id custom-type="elpub" pub-id-type="custom">medlit-4471</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРОФИЛАКТИЧЕСКАЯ ТОКСИКОЛОГИЯ И ГИГИЕНИЧЕСКОЕ НОРМИРОВАНИЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PREVENTIVE TOXICOLOGY AND HYGIENIC STANDARTIZATION</subject></subj-group></article-categories><title-group><article-title>Полиморфизм кандидатных генов MTNR1B C/G (rs10830963) и TCF7L2 C/T (rs7903146) у детей как фактор риска формирования патологии гепатобилиарной системы в условиях контаминации биосред тяжёлыми металлами (на примере свинца)</article-title><trans-title-group xml:lang="en"><trans-title>Polymorphism of candidate genes MTNR1B C/G (rs10830963) and TCF7L2 C/T (rs7903146) in children as a risk factor for the development of hepatobiliary system pathology in conditions of contamination of biological media with heavy metals (using lead as an example)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4860-3145</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Долгих</surname><given-names>Олег Владимирович</given-names></name><name name-style="western" xml:lang="en"><surname>Dolgikh</surname><given-names>Oleg V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор мед. наук, зав. отд. иммунобиологических методов диагностики ФБУН «ФНЦ МПТ УРЗН», 614045, Пермь, Россия</p></bio><bio xml:lang="en"><p>DSc (Medicine), Head of the Department of Immunobiological Diagnostic Methods of the Federal Scientific Center for Medical and Preventive Health Risk Management Technologies, Perm, 614045, Russian Federation</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0114-3930</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Казакова</surname><given-names>Ольга Алексеевна</given-names></name><name name-style="western" xml:lang="en"><surname>Kazakova</surname><given-names>Olga A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Канд. биол. наук, ст. науч. сотр. – зав. лаб. иммуногенетики ФБУН «ФНЦ МПТ УРЗН», 614045, Пермь, Россия</p></bio><bio xml:lang="en"><p>PhD (Medicine), senior researcher of the Immunogenetics laboratory of the Federal Scientific Center for Medical and Preventive Health Risk Management Technologies, Perm, 614045, Russian Federation</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-8957-9164</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лучникова</surname><given-names>Виктория Александровна</given-names></name><name name-style="western" xml:lang="en"><surname>Luchnikova</surname><given-names>Viktoria A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мл. науч. сотр. лаб. иммунологии и аллергологии ФБУН «ФНЦ МПТ УРЗН», 614045, Пермь, Россия</p><p>e-mail: bezdenezhka@yandex.ru</p></bio><bio xml:lang="en"><p>Junior researcher at the Laboratory of Immunology and allergology of the Federal Scientific Center for Medical and Preventive Health Risk Management Technologies, Perm, 614045, Russian Federation</p><p>e-mail: bezdenezhka@yandex.ru</p></bio><email xlink:type="simple">bezdenezhka@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФБУН «Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения» Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Scientific Center for Medical and Preventive Health Risk Management Technologies</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>17</day><month>12</month><year>2024</year></pub-date><volume>103</volume><issue>11</issue><fpage>1417</fpage><lpage>1422</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Долгих О.В., Казакова О.А., Лучникова В.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Долгих О.В., Казакова О.А., Лучникова В.А.</copyright-holder><copyright-holder xml:lang="en">Dolgikh O.V., Kazakova O.A., Luchnikova V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rjhas.ru/jour/article/view/4471">https://www.rjhas.ru/jour/article/view/4471</self-uri><abstract><sec><title>Введение</title><p>Введение. Влияние свинца на здоровье с учётом вероятного механизма его молекулярных взаимодействий в организме изучено недостаточно.</p><p>Цель исследования – оценка полиморфизма генов MTNR1B C/G (rs10830963) и TCF7L2 C/T (rs7903146) у детей как фактора риска формирования патологии гепатобилиарной системы в условиях контаминации биосред тяжёлыми металлами (на примере свинца).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Выполнено обследование 93 детей 3–6 лет (39 детей с патологией гепатобилиарной системы и 54 условно здоровых ребёнка), подверженных низкоуровневой аэрогенной экспозиции свинцом (0,1ПДКс.с.) при среднесуточной дозе 0,4 · 10–3 мкг/кг · день. Выполнена оценка частотности аллелей и генотипов кандидатных генов MTNR1B C/G (rs10830963) и TCF7L2-1 C/T (rs7903146), ассоциированных с уровнями контаминации биосред свинцом и патологией гепатобилиарной системы.</p></sec><sec><title>Результаты</title><p>Результаты. Установлено, что у детей группы наблюдения показана достоверно высокая частота встречаемости G-вариантного аллеля (OR = 1,92; CI: 1,04–3,54) и GG-генотипа (OR = 7,80; CI: 1,58–38,51; p &lt; 0,05) гена MTNR1B, а также C дикого аллеля (OR = 2,07; CI: 1,02–4,20; p &lt; 0,05) и CC-генотипа (OR = 2,42; CI: 1,02–5,70; p &lt; 0,05) гена TCF7L2-1, которые выступают в качестве факторов риска (RR = 1,20–1,43) формирования патологии гепатобилиарной системы, отягощённой контаминацией крови свинцом.</p></sec><sec><title>Ограничения исследования</title><p>Ограничения исследования. Ограниченность выборки, необходимость верификации результатов в дальнейших наблюдениях.</p></sec><sec><title>Заключение</title><p>Заключение. Установлено, что дети с патологией гепатобилиарной системы, проживающие на территории, характеризующейся хронической низкоуровневой аэрогенной экспозицией свинцом 0,4 · 10–3 мг/кг · день (0,1 ПДКс.с.), отличались избыточным уровнем содержания свинца в крови, а также нарушениями биоритмов гладкой мускулатуры желчевыводящих путей, сопряжённых с риском (RR = 1,20–1,43) развития патологии гепатобилиарной системы в условиях G-вариантного аллеля (OR = 1,92; CI: 1,04–3,54; p &lt; 0,05) гена MTNR1B, а также C дикого аллеля (OR = 2,07; CI: 1,02–4,20; p &lt; 0,05) гена TCF7L2-1.</p><p>Соблюдение этических стандартов. Исследование проведено с соблюдением основ Хельсинкской декларации ВМА и одобрено ЛЭК ФБУН «ФНЦ медико-профилактических технологий управления рисками здоровью населения» (протокол заседания № 4 от 17.01.2022 г.). Все участники дали информированное добровольное письменное согласие на участие в исследовании.</p></sec><sec><title>Участие авторов</title><p>Участие авторов: Долгих О.В. – концепция и дизайн исследования, редактирование; Казакова О.А. – дизайн исследования, обработка данных, написание текста; Лучникова В.А. – сбор материала и обработка данных. Все соавторы – утверждение окончательного варианта статьи, ответственность за целостность всех частей статьи.</p></sec><sec><title>Конфликт интересов</title><p>Конфликт интересов. Авторы заявляют об отсутствии явных и потенциальных конфликтов интересов в связи с публикацией данной статьи.</p></sec><sec><title>Финансирование</title><p>Финансирование. Исследование не имело финансовой поддержки.</p></sec><sec><title>Поступила</title><p>Поступила: 23.09.2024 / Принята к печати: 19.11.2024 / Опубликована: 17.12.2024</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Lead impact on health considering likely pathways of its molecular interactions in the body have not been given sufficient attention by researchers.</p><p>The aim of this study was to assess polymorphism of the MTNR1B C/G (rs10830963) and TCF7L2 C/T (rs7903146) genes in children as a risk factor of hepatobiliary pathology in case of heavy metal contamination in biological media (exemplified by lead).</p></sec><sec><title>Materials and methods</title><p>Materials and methods. We examined ninety three 3–6 years children (39 children had hepatobiliary pathology and 54 children were considered healthy) who were exposed to low-dose airborne lead (0.1MPLa.d.), the average daily dose being 0.4 · 10–3 µg/kg · day. We estimated frequency of alleles and genotypes of the candidate genes MTNR1B C/G (rs10830963) and TCF7L2-1 C/T (rs7903146) associated with levels of lead contamination in biological media and hepatobiliary pathology.</p></sec><sec><title>Results</title><p>Results. The children from the observation group were established to have authentically high frequency of the G allele (OR=1.92, CI: 1.04–3.54) and GG genotype (OR=7.80, CI: 1.58–38.51; p&lt;0.05) of the MTNR1B gene, as well as C wild type allele (OR=2.07, CI: 1.02–4.20; p&lt;0.05) and CC genotype (OR=2.42, CI: 1.02–5.70; p&lt;0.05) of the TCF7L2-1 gene, which were risk factors (RR=1.20–1.43) of developing hepatobiliary pathology aggravated by lead contamination in blood.</p></sec><sec><title>Limitations</title><p>Limitations. Limited sampling, the need to verify the results in further observations.</p></sec><sec><title>Conclusion</title><p>Conclusion. The study established children with hepatobiliary pathology who lived under long-term low-dose exposure to airborne lead at the dose of 0.4 · 10–3 µg/kg · day (0.1MPLa.d.) to have elevated lead levels in blood and impaired biorhythms of smooth muscles in the bile duct combined with the risk (RR=1.20–1.43) of developing hepatobiliary pathology in carriers of G allele (OR=1.92, CI: 1.04–3.54; p&lt;0.05) of the MTNR1B gene as well as C wild type allele (OR=2.07, CI: 1.02–4.20; p&lt;0.05) of the TCF7L2-1 gene.</p><p>Compliance with ethical standards. The study was conducted in compliance with the principles of the Helsinki Declaration of the BMA and approved by the LEK of the Federal State Budgetary Institution “FNC of Medical and Preventive Technologies for Public Health Risk Management” (Minutes of meeting No. 4 dated 01/17/2022). All participants gave informed voluntary written consent to participate in the study.</p></sec><sec><title>Contribution</title><p>Contribution: Dolgikh O.V. – concept and design of the study, editing the text; Kazakova O.A. – research design, data processing, text writing; Luchnikova V.A. – material collection and data processing. All authors are responsible for the integrity of all parts of the manuscript and approval of its final version.</p></sec><sec><title>Conflict of interest</title><p>Conflict of interest. The authors declare no conflict of interest.</p></sec><sec><title>Acknowledgement</title><p>Acknowledgement. The study had no sponsorship.</p></sec><sec><title>Received</title><p>Received: September 23, 2024 / Accepted: November 19, 2024 / Published: December 17, 2024</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>свинец</kwd><kwd>относительный риск</kwd><kwd>ген мелатонинового рецептора MTNR1B</kwd><kwd>ген транскрипционного фактора 7 типа 2 переносчика глюкозы TCF7L2</kwd><kwd>патология гепатобилиарной системы</kwd><kwd>дети</kwd></kwd-group><kwd-group xml:lang="en"><kwd>lead</kwd><kwd>relative risk</kwd><kwd>melatonin receptor MTNR1B gene</kwd><kwd>transcription factor 7-like 2 glucose transporter gene TCF7L2</kwd><kwd>hepatobiliary pathology</kwd><kwd>children</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kern M., Audesirk T., Audesirk G. Effects of inorganic lead on the differentiation and growth of cortical neurons in culture. Neurotoxicology. 1993; 14(2–3): 319–27.</mixed-citation><mixed-citation xml:lang="en">Kern M., Audesirk T., Audesirk G. Effects of inorganic lead on the differentiation and growth of cortical neurons in culture. Neurotoxicology. 1993; 14(2–3): 319–27.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sánchez-Martín F.J., Fan Y., Lindquist D.M., Xia Y., Puga A. Lead induces similar gene expression changes in brains of gestationally exposed adult mice and in neurons differentiated from mouse embryonic stem cells. PLoS One. 2013; 8(11): e80558. https://doi.org/10.1371/journal.pone.0080558</mixed-citation><mixed-citation xml:lang="en">Sánchez-Martín F.J., Fan Y., Lindquist D.M., Xia Y., Puga A. Lead induces similar gene expression changes in brains of gestationally exposed adult mice and in neurons differentiated from mouse embryonic stem cells. PLoS One. 2013; 8(11): e80558. https://doi.org/10.1371/journal.pone.0080558</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hernández-Plata E., Quiroz-Compeán F., Ramírez-Garcia G., Barrientos E.Y., Rodríguez-Morales N.M., Flores A., et al. Melatonin reduces lead levels in blood, brain and bone and increases lead excretion in rats subjected to subacute lead treatment. Toxicol. Lett. 2015; 233(2): 78–83. https://doi.org/10.1016/j.toxlet.2015.01.009</mixed-citation><mixed-citation xml:lang="en">Hernández-Plata E., Quiroz-Compeán F., Ramírez-Garcia G., Barrientos E.Y., Rodríguez-Morales N.M., Flores A., et al. Melatonin reduces lead levels in blood, brain and bone and increases lead excretion in rats subjected to subacute lead treatment. Toxicol. Lett. 2015; 233(2): 78–83. https://doi.org/10.1016/j.toxlet.2015.01.009</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Арушанян Э.Б., Щетинин Е.В. Значение мелатонина для деятельности печени. Медицина. 2018; (2): 35–50. https://doi.org/10.29234/2308-9113-2018-6-2-35-50 https://elibrary.ru/uuxhou</mixed-citation><mixed-citation xml:lang="en">Arushanyan E.B., Shchetinin E.V. Significance of melatonin for the liver activity. Meditsina. 2018; (2): 35–50. https://doi.org/10.29234/2308-9113-2018-6-2-35-50 https://elibrary.ru/uuxhou (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ceci L., Chen L., Baiocchi L., Wu N., Kennedy L., Carpino G., et al. Prolonged administration of melatonin ameliorates liver phenotypes in cholestatic murine model. Cell. Mol. Gastroenterol. Hepatol. 2022; 14(4): 877–904. https://doi.org/10.1016/j.jcmgh.2022.07.007</mixed-citation><mixed-citation xml:lang="en">Ceci L., Chen L., Baiocchi L., Wu N., Kennedy L., Carpino G., et al. Prolonged administration of melatonin ameliorates liver phenotypes in cholestatic murine model. Cell. Mol. Gastroenterol. Hepatol. 2022; 14(4): 877–904. https://doi.org/10.1016/j.jcmgh.2022.07.007</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Meng Z., Guo S., Dong X., Wang Q., Hu D., Liu X., et al. Astrocyte-ablation of Mtnr1b increases anxiety-like behavior in adult male mice. J. Integr. Neurosci. 2023; 22(6): 154. https://doi.org/10.31083/j.jin2206154</mixed-citation><mixed-citation xml:lang="en">Meng Z., Guo S., Dong X., Wang Q., Hu D., Liu X., et al. Astrocyte-ablation of Mtnr1b increases anxiety-like behavior in adult male mice. J. Integr. Neurosci. 2023; 22(6): 154. https://doi.org/10.31083/j.jin2206154</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">da Silveira Cruz-Machado S., Pinato L., Tamura E.K., Carvalho-Sousa C.E., Markus R.P. Glia-pinealocyte network: the paracrine modulation of melatonin synthesis by tumor necrosis factor (TNF). PLoS One. 2012; 7(7): e40142. https://doi.org/10.1371/journal.pone.0040142</mixed-citation><mixed-citation xml:lang="en">da Silveira Cruz-Machado S., Pinato L., Tamura E.K., Carvalho-Sousa C.E., Markus R.P. Glia-pinealocyte network: the paracrine modulation of melatonin synthesis by tumor necrosis factor (TNF). PLoS One. 2012; 7(7): e40142. https://doi.org/10.1371/journal.pone.0040142</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sompub K., Krityakiarana W., Jongkamonwiwat N., Mukda S., Phansuwan-Pujito P., Govitrapong P. Effects of melatonin on myelin-associated inhibitors after severe crush spinal cord injury in a mouse model. Front. Cell. Neurosci. 2016; 10. https://doi.org/10.3389/conf.fncel.2016.36.00156</mixed-citation><mixed-citation xml:lang="en">Sompub K., Krityakiarana W., Jongkamonwiwat N., Mukda S., Phansuwan-Pujito P., Govitrapong P. Effects of melatonin on myelin-associated inhibitors after severe crush spinal cord injury in a mouse model. Front. Cell. Neurosci. 2016; 10. https://doi.org/10.3389/conf.fncel.2016.36.00156</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Villapol S., Fau S., Renolleau S., Biran V., Charriaut-Marlangue C., Baud O. Melatonin promotes myelination by decreasing white matter inflammation after neonatal stroke. Pediatr. Res. 2011; 69(1): 51–5. https://doi.org/10.1203/pdr.0b013e3181fcb40b</mixed-citation><mixed-citation xml:lang="en">Villapol S., Fau S., Renolleau S., Biran V., Charriaut-Marlangue C., Baud O. Melatonin promotes myelination by decreasing white matter inflammation after neonatal stroke. Pediatr. Res. 2011; 69(1): 51–5. https://doi.org/10.1203/pdr.0b013e3181fcb40b</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Vogan K. TCF7L2 and liver function. Nat. Genet. 2013; 45(2): 123. https://doi.org/10.1038/ng.2548</mixed-citation><mixed-citation xml:lang="en">Vogan K. TCF7L2 and liver function. Nat. Genet. 2013; 45(2): 123. https://doi.org/10.1038/ng.2548</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Madhu S.V., Aslam M., Mishra B.K., Mehndiratta M. Rotational night shift work adversely affects expression of TCF7L2 and PPAR-γ genes among healthcare workers with normal glucose tolerance. Int. J. Diabetes Dev. Ctries. 2023; 43(5): 816–20. https://doi.org/10.1007/s13410-022-01159-z</mixed-citation><mixed-citation xml:lang="en">Madhu S.V., Aslam M., Mishra B.K., Mehndiratta M. Rotational night shift work adversely affects expression of TCF7L2 and PPAR-γ genes among healthcare workers with normal glucose tolerance. Int. J. Diabetes Dev. Ctries. 2023; 43(5): 816–20. https://doi.org/10.1007/s13410-022-01159-z</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Norton L., Chen X., Fourcaudot M., Acharya N.K., DeFronzo R.A., Heikkinen S. The mechanisms of genome-wide target gene regulation by TCF7L2 in liver cells. Nucleic Acids Res. 2014; 42(22): 13646–61. https://doi.org/10.1093/nar/gku1225</mixed-citation><mixed-citation xml:lang="en">Norton L., Chen X., Fourcaudot M., Acharya N.K., DeFronzo R.A., Heikkinen S. The mechanisms of genome-wide target gene regulation by TCF7L2 in liver cells. Nucleic Acids Res. 2014; 42(22): 13646–61. https://doi.org/10.1093/nar/gku1225</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lipiec M.A., Bem J., Koziński K., Chakraborty C., Urban-Ciećko J., Zajkowski T., et al. TCF7L2 regulates postmitotic differentiation programmes and excitability patterns in the thalamus. Development. 2020; 147(16): dev190181. https://doi.org/10.1242/dev.190181</mixed-citation><mixed-citation xml:lang="en">Lipiec M.A., Bem J., Koziński K., Chakraborty C., Urban-Ciećko J., Zajkowski T., et al. TCF7L2 regulates postmitotic differentiation programmes and excitability patterns in the thalamus. Development. 2020; 147(16): dev190181. https://doi.org/10.1242/dev.190181</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Polcyn R., Capone M., Hossain A., Matzelle D., Banik N.L., Haque A. Neuron specific enolase is a potential target for regulating neuronal cell survival and death: implications in neurodegeneration and regeneration. Neuroimmunol. Neuroinflamm. 2017; 4: 254–7. https://doi.org/10.20517/2347-8659.2017.59</mixed-citation><mixed-citation xml:lang="en">Polcyn R., Capone M., Hossain A., Matzelle D., Banik N.L., Haque A. Neuron specific enolase is a potential target for regulating neuronal cell survival and death: implications in neurodegeneration and regeneration. Neuroimmunol. Neuroinflamm. 2017; 4: 254–7. https://doi.org/10.20517/2347-8659.2017.59</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Жукова И.А., Алифирова В.М., Жукова Н.Г. Нейронспецифическая енолаза как неспецифический маркер нейродегенеративного процесса. Бюллетень сибирской медицины. 2011; 10(2): 15–21. https://elibrary.ru/nulijn</mixed-citation><mixed-citation xml:lang="en">Zhukova I.A., Alifirova V.M., Zhukova N.G. Neurospecific enolase as a nonspecific neurodegenerative process marker. Byulleten’ sibirskoi meditsiny. 2011; 10(2): 15–21. https://elibrary.ru/nulijn (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Yan Z., Shi X., Wang H., Si C., Liu Q., Du Y. Neurotrophin-3 promotes the neuronal differentiation of BMSCs and improves cognitive function in a rat model of Alzheimer’s disease. Front. Cell. Neurosci. 2021; 15: 629356. https://doi.org/10.3389/fncel.2021.629356</mixed-citation><mixed-citation xml:lang="en">Yan Z., Shi X., Wang H., Si C., Liu Q., Du Y. Neurotrophin-3 promotes the neuronal differentiation of BMSCs and improves cognitive function in a rat model of Alzheimer’s disease. Front. Cell. Neurosci. 2021; 15: 629356. https://doi.org/10.3389/fncel.2021.629356</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Chalazonitis A. Neurotrophin-3 as an essential signal for the developing nervous system. Mol. Neurobiol. 1996; 12(1): 39–53. https://doi.org/10.1007/BF02740746</mixed-citation><mixed-citation xml:lang="en">Chalazonitis A. Neurotrophin-3 as an essential signal for the developing nervous system. Mol. Neurobiol. 1996; 12(1): 39–53. https://doi.org/10.1007/BF02740746</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Pae C.U., Marks D.M., Han C., Patkar A.A., Steffens D. Does neurotropin-3 have a therapeutic implication in major depression? Int. J. Neurosci. 2008; 118(11): 1515–22. https://doi.org/10.1080/00207450802174589</mixed-citation><mixed-citation xml:lang="en">Pae C.U., Marks D.M., Han C., Patkar A.A., Steffens D. Does neurotropin-3 have a therapeutic implication in major depression? Int. J. Neurosci. 2008; 118(11): 1515–22. https://doi.org/10.1080/00207450802174589</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hayes G., Pinto J., Sparks S.N., Wang C., Suri S., Bulte D.P. Vascular smooth muscle cell dysfunction in neurodegeneration. Front. Neurosci. 2022; 16: 1010164. https://doi.org/10.3389/fnins.2022.1010164</mixed-citation><mixed-citation xml:lang="en">Hayes G., Pinto J., Sparks S.N., Wang C., Suri S., Bulte D.P. Vascular smooth muscle cell dysfunction in neurodegeneration. Front. Neurosci. 2022; 16: 1010164. https://doi.org/10.3389/fnins.2022.1010164</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kıray H., Lindsay S.L., Hosseinzadeh S., Barnett S.C. The multifaceted role of astrocytes in regulating myelination. Exp. Neurol. 2016; 283(Pt. B): 541–9. https://doi.org/10.1016/j.expneurol.2016.03.009</mixed-citation><mixed-citation xml:lang="en">Kıray H., Lindsay S.L., Hosseinzadeh S., Barnett S.C. The multifaceted role of astrocytes in regulating myelination. Exp. Neurol. 2016; 283(Pt. B): 541–9. https://doi.org/10.1016/j.expneurol.2016.03.009</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Коломейчук С.Н., Корнева В.А., Кузнецова Т.Ю., Коростовцева Л.С., Бочкарев М.В., Свиряев Ю.В. и др. Роль полиморфных вариантов генов рецептора мелатонина MTNR1A и MTNR1B в регуляции эластичности сосудистой стенки у лиц без артериальной гипертензии. Российский кардиологический журнал. 2023; 28(S6): 51–2. https://elibrary.ru/miocdw</mixed-citation><mixed-citation xml:lang="en">Kolomeichuk S.N., Korneva V.A., Kuznetsova T.Yu., Korostovtseva L.S., Bochkarev M.V., Sviryaev Yu.V., et al. The role of polymorphic variants of the MTNR1A and MTNR1B melatonin receptor genes in the regulation of vascular wall elasticity in people without hypertension. Rossiiskii kardiologicheskii zhurnal. 2023; 28(S6): 51–2. https://elibrary.ru/miocdw (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Soto-Arredondo K.J., Robles J., Díaz-Cervantes E., Ruiz-Ramírez C., García-Revilla M.A., Wrobel K., et al. Effects of lead and lead-melatonin exposure on protein and gene expression of metal transporters, proteins and the copper/zinc ratio in rats. Biometals. 2018; 31(5): 859–71. https://doi.org/10.1007/s10534-018-0127-1</mixed-citation><mixed-citation xml:lang="en">Soto-Arredondo K.J., Robles J., Díaz-Cervantes E., Ruiz-Ramírez C., García-Revilla M.A., Wrobel K., et al. Effects of lead and lead-melatonin exposure on protein and gene expression of metal transporters, proteins and the copper/zinc ratio in rats. Biometals. 2018; 31(5): 859–71. https://doi.org/10.1007/s10534-018-0127-1</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Omeiza N.A., Abdulrahim H.A., Alagbonsi A.I., Ezurike P.U., Soluoku T.K., Isiabor H., et al. Melatonin salvages lead-induced neuro-cognitive shutdown, anxiety, and depressive-like symptoms via oxido-inflammatory and cholinergic mechanisms. Brain Behav. 2021; 11(8): e2227. https://doi.org/10.1002/brb3.2227</mixed-citation><mixed-citation xml:lang="en">Omeiza N.A., Abdulrahim H.A., Alagbonsi A.I., Ezurike P.U., Soluoku T.K., Isiabor H., et al. Melatonin salvages lead-induced neuro-cognitive shutdown, anxiety, and depressive-like symptoms via oxido-inflammatory and cholinergic mechanisms. Brain Behav. 2021; 11(8): e2227. https://doi.org/10.1002/brb3.2227</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
